Satoshi Miyamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Satoshi Miyamoto has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Hirokazu Kanegane
Department of Child Health and Development, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo Japan
3 shared publications - Katsutsugu Umeda
Department of Pediatrics, Graduate School of Medicine, Kyoto University, Kyoto
3 shared publications Ryosuke Wakatsuki
Department of Pediatrics and Developmental Biology Institute of Science Tokyo Tokyo Japan
3 shared publicationsAkihiro Hoshino
Deparment of Child Health and Development, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo, Japan
2 shared publications- Hirotoshi Sakaguchi
National Center for Child Health and Development
2 shared publications Ken Tabuchi
Japanese Data Center for Hematopoietic Cell Transplantation Nagoya Japan
2 shared publications
Latest Publications
- 25 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Revisiting Related Cord Blood Transplantation: Successful HLA‐Matched Sibling Cord Blood Transplantation for LIG4 Deficiency
- 25 July 2026
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 73 (10)
Revisiting Related Cord Blood Transplantation: Successful HLA‐Matched Sibling Cord Blood Transplantation for LIG4 Deficiency
- 17 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 853.e1-853.e3
Posttransplant Chimerism Estimation Using Variant-Specific ddPCR in Inborn Errors of Immunity
- 17 April 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (7) , 853.e1-853.e3
Posttransplant Chimerism Estimation Using Variant-Specific ddPCR in Inborn Errors of Immunity
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1369-1379
Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders
Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.
- 18 February 2026
- Published by Wiley in British Journal of Haematology
- Vol. 208 (4) , 1369-1379
Utility of transplant conditioning intensity score in allogeneic haematopoietic stem cell transplantation for genetic disorders
Summary: In allogeneic haematopoietic stem cell transplantation (allo‐HSCT) for genetic disorders (GDs), predicting outcomes using the currently used myeloablative/reduced‐intensity conditioning classification is challenging. We examined the utility of the transplant conditioning intensity (TCI) score in allo‐HSCT for GDs. We retrospectively analysed 1077 patients who underwent first allo‐HSCT for GDs between 1987 and 2018. While no significant difference was observed in 3‐year non‐relapse mortality (NRM) between the myeloablative and reduced‐intensity conditioning group, 3‐year NRM in the TCI score ≥4.0 (TCI‐high) group (17.3%) was higher than that in the TCI score 0.5–3.5 (TCI‐low/intermediate) group (11.6%, p = 0.013). Multivariate analysis identified a high TCI score as a significant factor for NRM (HR 1.56, p = 0.011). Infection‐related mortalities were more prevalent in the TCI‐high group (7.9%) compared with the TCI‐low/intermediate group (3.2%). In contrast, patients in the TCI‐high group achieved a significantly higher rate of complete donor chimerism (71.7%) than those in the TCI‐low/intermediate group (62.2%, p = 0.022). TCI score is a valuable tool for predicting outcomes after allo‐HSCT for GDs as well as for guiding the selection of conditioning regimens tailored to the unique characteristics of GDs.
- 12 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (2) , 203.e1-203.e11
Effect of Inflammatory Bowel Disease on Clinical Outcomes of Hematopoietic Cell Transplantation for Inborn Errors of Immunity
- 12 November 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (2) , 203.e1-203.e11
Effect of Inflammatory Bowel Disease on Clinical Outcomes of Hematopoietic Cell Transplantation for Inborn Errors of Immunity
- 19 August 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (10) , 102796
Refractory mediastinal pyogenic lymphadenitis in a patient with chronic mucocutaneous candidiasis
- 19 August 2025
- Published by Elsevier in Journal of Infection and Chemotherapy
- Vol. 31 (10) , 102796
Refractory mediastinal pyogenic lymphadenitis in a patient with chronic mucocutaneous candidiasis